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All hospitalizations and deaths due to DKA between 1996 and 2016 were identified in 4758 adults 
with T1D from the Finnish Diabetic Nephropathy Study (FinnDiane), and a cohort of 16224 adults 
with T1D from the Finnish general population.  
Results 
Between 1996 and 2015, there were 1228 DKA events in the FinnDiane participants (1.4/100 person-
years) and 4914 DKA vents (1.8/100 person-years) in the adults with T1D from the general 
population. The majority were hospitalized only once. There was a modest increase in the frequency 
of DKA in the FinnDiane over the follow-up (~2.4%/year [95% CI 0.3-4.5%]; p=0.03). Predictors of 
DKA were glucose control, CSII, smoking and alcohol consumption, raised HDL cholesterol and 
triacylglycerides. Diabetic nephropathy and renal impairment were associated with DKA; patients 
with end-stage renal disease, macroalbuminuria and microalbuminuria had 2.09- (95% CI 1.40-3.12), 
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excretion rate, respectively.  Patients with an eGFR<60 ml/min/1.73m2 were also more likely to be 
hospitalized for DKA (HR 1.71, [1.26-2.67]). 
Conclusions 
DKA remains a common cause of hospitalization in individuals with longstanding T1D. These data 
suggest that the goal to use SGLT2 inhibitors for their vasculo- and renoprotective actions may be 



























ational Library of H

















Diabetic ketoacidosis (DKA) is one of the most important emergencies in T1D (T1D) and a common 
reason for hospitalization (1). Despite improving diabetes care and new technologies for insulin 
delivery and glucose monitoring, at least three in every hundred persons with T1D may be 
hospitalised annually in the United States (US) and this incidence appears to be increasing both in 
the US (2, 3) and in other countries (4). The total health care cost associated with DKA in the US has 
been estimated to be over 5 billion dollars annually (1). Although mortality rates from DKA are 
declining, it remains one of the biggest contributors to loss of life years associated with T1D (5, 6). 
Many DKA events are observed in and around the time of the diagnosis of T1D, or during the first 
few years of management when titration, accidental omission or poor adherence may sometimes 
result in inadequate insulin therapy, especially in children and adolescents. Cross-sectional studies 
exploring the prevalence of DKA are therefore potentially dominated by newly-diagnosed cases of 
T1D, especially in young individuals and their associated risk factors. These risks may not be the 
same as older adults with well-established diabetes, in whom the annual incidence of acute DKA is 
lower (2) but likely remains significant over time (6). 
The long-term natural history of DKA and its risks are poorly understood. Determining the ongoing 
risks for DKA in adults with established T1D is also now particularly important, as the future 
relevance of vasculo-protective outcomes of Sodium GLucose coTransporter (SGLT)2 inhibitors may 
be offset by an increased risk of DKA following treatment with these agents in this setting (7).  In 
this study, we examine the long-term incidence and predictors of hospitalization for DKA in a 
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retrospective cohort of 16,224 adults with T1D from the Finnish general population followed over 
the same time period. 
Methods 
The Finnish Diabetic Nephropathy Study (FinnDiane) is an ongoing, nationwide, multicenter study, 
initiated in order to identify genetic and environmental risk factors for diabetic complications, with 
special emphasis on diabetic kidney disease in patients with type 1 diabetes. A detailed description 
of the FinnDiane recruitment protocol has previously been presented (8). Briefly, adult patients (≥18 
years old) with type 1 diabetes across Finland were asked to participate, and the participation rate 
was 78%. Type 1 diabetes was defined as insulin dependence and C-peptide <0.30 nmol/l, age at 
onset of diabetes <40 years and insulin treatment initiated within 1 year of diagnosis. The study 
protocol was in accordance with the principles of the Declaration of Helsinki as revised in 2000 and 
was approved by the Ethical Committee of Helsinki and Uusimaa Hospital District. Written informed 
consents were obtained from each FinnDiane patient.  
The baseline visit for participants occurred between the years 1994 and 2015 (n=4758), at which 
time participants underwent a thorough clinical examination and blood and urine samples were 
collected. Information on the presence of diabetic complications including renal and cardiovascular 
disease were obtained from the medical files by the attending physician using a standardized 
questionnaire. In addition, albuminuria status was determined based on measurements of urinary 
albumin excretion rate (UAER) from at least two timed overnight (g/min) or 24h urine (mg/24h) 
collections. Normoalbuminuria was defined when in at least two out of three urinary samples UAER 
was <20 μg/min or <30 mg/24 h; microalbuminuria, when UAER ≥20 and <200 μg/min or ≥30 and 
<300 mg/24 h; or macroalbuminuria, when UAER ≥200 μg/min or ≥300 mg/24 h; end-stage renal 
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determined at a central laboratory by a kinetic Jaffe method using a Hitachi 911 autoanalyzer until 
January 2002. Thereafter it was determined by a photometric enzymatic method using a Hitachi 917 
or Modular analyser. We have taken account of this change in the measurement of creatinine by 
using the modifying coefficient (1/1.0465). The estimated glomerular filtration rate (eGFR) was 
calculated using the CKD-EPI formula. 
Patients filled in questionnaires regarding their lifestyle, including their smoking habits, alcohol 
consumption and socioeconomic status. Serial HbA1c values from the medical files were obtained 
and intra-individual mean and coefficient of variation (CV) were calculated. The CV was calculated 
as a ratio of intra-individual standard deviation and mean.  
Ascertainment of outcomes 
For each participant in the FinnDiane cohort, the composite outcome of admission to hospital, 
attendance at an emergency department or specialized outpatient care with a diagnosis of DKA or 
death from DKA (hitherto denoted as DKA hospitalization) was determined. Hospitalization for DKA 
was ascertained from the Finnish Care Register for Health Care (HILMO) database that collects all 
discharges from Finnish hospitals (including specialized outpatient care) and associated diagnosis 
and treatment codes. All events in which the International Classification of Disease (ICD) 9th Revision 
code of 2501B (1987-1995 for prevalent cases before visit) and the 10th Revision code of E10.1 
(1996-2015) were used were designated as DKA. However, if there were several successive 
admissions within less than five days they were calculated as one event. Fatal DKA events were 
drawn from the Finnish Cause of Death Register.  
For determining the frequency of DKA hospitalization in FinnDiane participants, all DKA events 
between 1996 and 2015 were determined, including events that occurred prior to enrollment and 
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two years of their diabetes were excluded, as a recent diagnosis, honeymoon phases and 
subsequent titration of insulin may confound an analysis of DKA incidence in these cases. Outcomes 
follow-up commenced from the start of their third year of diabetes, from 18 years of age or the year 
1996, whichever was most recent. For analysis of the predictors of incident DKA, only DKA events 
that occurred after the baseline visit were considered as the outcome. A history of prior DKA was 
determined as a coded diagnosis for hospitalization between 1987 and baseline visit in the HILMO 
dataset and used as a predictive variable.  
Retrospective cohort validation 
The frequency of hospitalization for DKA over the same time period was also determined in a larger 
retrospective cohort of adults with type 1 diabetes in Finland. To do this, all adults (age >18) with 
T1D (defined by a diagnosis of diabetes under the age of 30 years and ongoing insulin requirements) 
present on January 1st 1994 were identified using the National Institute for Health and Welfare 
database, as previously described (9-11).  Admission to hospital for DKA between January 1996 and 
December 2015 was then retrospectively identified using the HILMO hospitalization and ICD-10 
codes as detailed above. This inclusion strategy effectively excluded events that occurred in patients 
with potentially less than two years duration of diabetes. The study has permissions from the Finnish 
National Institute for Health and Welfare (THL/786/6.02.00/2016) and Statistics Finland (TK53-26-
16).  
Statistical methods 
Crude DKA rates and DKA mortality rates were calculated per 100 person-years with 95% Poisson 
confidence intervals. We used linear regression to model the age-standardized prevalence curves. 
In order to model the prognostic variables related to DKA, Cox regression analyses were conducted 
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Kaplan-Meier survival analyses and the log rank test was used to test for between-group differences. 
Poisson regression was used to model predictors of all DKA events including recurrent events. 
Statistical analyses were performed using SAS 9.4 version (SAS Institute Inc, Cary, NC, USA).   
Results 
Baseline characteristics of the FinnDiane cohort 
The baseline characteristics of individuals experiencing hospitalization for DKA during the 
prospective follow-up phase are shown in Table 1, compared to those not experiencing DKA during 
follow-up. Those with at least one DKA hospitalization had more frequently prior DKA, insulin pump 
therapy, higher HbA1c, mean and variability of serial HbA1c, dose of weekly alcohol consumption, 
insulin dose, total cholesterol and triglycerides, but lower age at onset of diabetes, BMI and 
estimated glucose disposal rate compared with patients without DKA. In addition, they had more 
likely smoking history, hypertension, kidney disease, severe diabetic retinopathy. Patients with two 
or more DKAs had further more likely history of excess alcohol usage.  
The incidence of hospitalization for DKA for participants in the FinnDiane cohort 
Between 1996 and 2015, there were 1206 hospitalizations for DKA and 22 fatal DKA events in the 
FinnDiane participants resulted in an overall rate of 1.4 per 100 person-years. The proportion 
individuals managed as inpatients was similar in those with eGFR<60 (62.4%) and with eGFR≥60 
(63.0%) (p=0.81). The annualized frequency of DKA events is shown in Figure 1A. There was a modest 
but significant increase in the frequency of DKAs over this time period (~2.4% per year (95% CI 0.3-
4.5%, p<0.03).  The modelled mean incidence was 1.1 per 100 person-years in 1996 while in 2015 it 
had risen to 1.6 per 100 person-years. These DKA events occurred in 617 participants (13.0%), 
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a single occasion in this time period (65%). Notably the frequency of these “one off” DKAs remained 
constant in this cohort (Figure 1A).   
Predictors of the incidence of hospitalization for DKA in the FinnDiane cohort 
From the time of their enrollment in the FinnDiane cohort, there were 969 non-fatal or fatal DKAs 
that occurred in 461 individuals over a median follow-up of 14.4 (10.6-16.6) years from baseline 
visit, equating to an overall event rate of 1.5 per 100 person-years only over the prospective follow-
up period. This number is slightly higher than the total hospitalizations detailed above, in the same 
individuals that occurred between 1996 and 2015. 
The majority of these DKAs (n=709, 73%) occurred in individuals that did not have a prior recorded 
DKA hospitalizations as an adult (aged >18) in the HILMO database, beyond the first two years of 
their diabetes.  Only 92 individuals (20%) experiencing a DKA hospitalization after enrollment had 
been hospitalized for DKA previously as an adult. 369 participants that had a DKA hospitalization 
event prior to enrollment, did not have a subsequent event after baseline during prospective follow-
up. 
After adjusting for a prior history of hospitalization for DKA, incident DKA in this population was 
independently associated with smoking and alcohol consumption at baseline, raised HDL cholesterol 
and plasma triglycerides concentrations, insulin pump therapy, and  poor glucose control (HbA1c) 
at baseline (Table 2). In particular, HbA1c levels over the course of follow-up and HbA1c variability 
trait were also independently associated with the incidence of hospitalization for DKA in adults with 
type 1 diabetes (Figure 2, Table 2) – such that those individuals with the best glycemic control and 
the least variability in their HbA1c also had the lowest incidence of DKA, while those individuals with 
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predictors of time to first event on Cox regression analysis were the same as those for all DKA events 
determined using Poisson regression (data not shown). 
Most importantly, diabetic nephropathy was associated with increased risk of DKA. After 
adjustment for these other risk factors patients with ESRD, macro- and microalbuminuria the risk 
was 2.09-fold (95% CI 1.40-3.12; p<0.0001), 1.65 (1.23-2.19; p=0.0007) and 0.87-fold (0.61-1.24; 
p=0.43) compared with patients with normal albumin excretion rate (Figure 3A). After excluding 
participants with ESRD, and adjusting for other risk factors, the presence of moderate to severe 
impairment in kidney function (eGFR <60 ml/min/1.73m2) remained associated with the incidence 
of hospitalization for DKA in adults with T1D, such that those individuals with eGFR<60 
ml/min/1.73m2 were twice as likely to be hospitalized for DKA (HR 1.71, [1.26-2.67]; p<0.0001) when 
compared to those with an eGFR>60 ml/min/1.73m2 (Table 2, Figure 3B). Hyperfiltration at baseline 
(eGFR >130 ml/min/1.73m2) was also associated with an increased risk of incident DKA (HR 2.35; 
95% CI 1.50-3.66; p=0.0002). However, after adjusting for glycemic control and glycemic variability 
during the study this association also became non-significant (p=0.07). Notably, the duration of T1D 
or the age at diagnosis were not associated with incidence of DKA in adults with type 1 diabetes. In 
addition, there was no association between incident DKA and sex, socioeconomic status, the control 
of LDL cholesterol or blood pressure or the presence of retinal complications at baseline (defined 
by the need for laser therapy). 
The frequency of hospitalization for DKA in the Finnish retrospective cohort 
In 15,149 adults with type 1 diabetes from the general population, over the same time period of 20 
years (1996-2015), there were 4771 hospitalizations for DKA and 143 fatal DKA events affecting 
2376 (15.7%) individuals, equating to an event rate of 1.8 per 100 person-years over this time 
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Figure 1B). The modelled incidence of hospitalization for DKA was 1.5 in 1996 per 100 person-years 
and 2.1 in 2015. Again, as in the FinnDiane cohort, most of the individuals experiencing DKA events 
in the retrospective cohort only had one event during this time period and the frequency of “one 
off” DKA events remained constant in this cohort (Figure 1B).  Mortality from DKA though rare, did 
not appear to decline with time (Figure 1B), though more patients were hospitalized with DKA over 
the same time period, meaning that DKA deaths as percentage of DKA events declined slightly, 
consistent with recent registry data (5, 6). 
Discussion 
DKA is an important and surprisingly common acute complication of T1D that results in increased 
healthcare costs (1-3), hospitalization (3, 4), and premature mortality (6, 12). In this contemporary 
prospective cohort of Finnish adults with T1D, one in tenth were hospitalised or died from DKA over 
a 14-year period, 36% of whom were hospitalised on more than one occasion. The rate of DKA was 
similar in adults with T1D from the Finnish general population than in participants in the FinnDiane 
study. Importantly, we report in both cohorts, the annual incidence rate in the same individuals did 
not decline over time and actually increased over the follow-up time period. Tragically, between 
1.8-3.0% of all DKA events leading to hospitalisation were associated with patient death. 
It is widely regarded that DKA is only a problem of early diabetes management, and becomes less 
likely in patients with established and ongoing insulin use and dedicated diabetes care. This 
assumption is supported by outcomes in the DCCT/EDIC cohort that showed a reduction in DKAs 
over the follow-up, with an incidence rate of approximately two cases per 100 person-years at 
baseline falling to no events at the 12-year follow-up, even in the standard treatment arm (13). 
Similarly, in a prospective follow-up of the Pittsburgh Epidemiology of Diabetes Complications (EDC) 
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follow-up (13). However, it is possible that the trials settings and close attention to diabetes control 
both during and after these studies may have progressively reduced the risk of DKA in these studies. 
In real-world data from adults with T1D in the FinnDiane study and adults with T1D in the Finnish 
general T1D population, DKA clearly did not decline, even as ‘one-off’ events. These data suggest 
that regardless of the duration of diabetes, the risk of DKA remains a constant companion. 
Previous cross-sectional registry-based studies exploring the predictors of DKA in populations have 
been inevitably dominated by new cases of T1D and the inclusion of children and young adults that 
have the highest risks of DKA. The clinical characteristics of these individuals therefore largely 
determine the reported risk factors for DKA in these reports. Such risks may be less relevant to the 
adult with established T1D, in whom longitudinal risks for DKA have not been well studied. The 
FinnDiane study is a large prospective cohort study designed specifically to look at complications in 
adults. Taking this prospective approach, and excluding all events in the first two years after 
diagnosis, we have been able to follow the incidence for hospitalization for DKA over 14 years within 
individual adults with T1D. We anticipate that this approach may be more useful in determining 
individuals who may be ketosis prone, or risk factors at baseline that may be usefully associated 
with subsequent DKA in the long term. 
Consistent with previous studies, in participants within FinnDiane cohort, poor glucose control was 
associated with an increased risk of hospitalization for DKA, which was clearly associated with both 
HbA1c at baseline, mean HbA1c during the follow-up and intra-individual HbA1c variability. It is 
likely that each of these markers capture some of the risk for DKA associated with recurrent 
hyperglycaemia, inadequate insulin therapy and/or non-adherence. The presence of elevated 
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glucose control during the study, and the least variability in HbA1c, hospitalization for DKA still 
occurred.  
In a recent metanalysis of trials, use of continuous insulin subcutaneous infusions (CSII) has also 
been associated with a higher incidence of reported diabetic ketoacidosis compared with 
conventional insulin therapy (14). The small percentage of participants in the FinnDiane cohort using 
insulin pumps at baseline (6.6%) also had a higher incidence of hospitalisation for DKA (HR = 2.44, 
95% CI 1.60-3.72, p<0.001) compared to those receiving standard insulin therapy. Beyond 
malfunction of insulin pump and/or catheter occlusion, the reasons behind this association are 
unclear but may include a failure to up-titrate insulin during acute illness. Notably, the association 
between DKA hospitalization and CSII was independent to poor baseline or achieved glucose 
control, which is often an indicator for pump initiation. 
Smoking and alcohol consumption were also independently associated with DKA in the FinnDiane 
cohort. While these may both be markers of risk-taking behaviours on non-adherent adults with 
T1D, the association remained significant after adjusting for ongoing glucose control and HbA1c 
variability. Ethanol is metabolised by the liver to generate acetic acid, and subsequently acetyl-CoA, 
which is both a substrate for ketogenesis and inhibitor of peripheral lipolysis. Oxidation of alcohol 
also increases generation of NADH, which inhibits gluconeogenesis and further drives the 
generation of beta-hydroxybutyrate. These pathways are augmented in the absence of insulin, 
making excess alcohol intake and T1D a potentially dangerous combination. It is possible that 
increasing alcohol consumption in Finland following a reduction of 33% in alcohol taxes in 2005–
2007, partly contributed to the increasing prevalence of DKA observed in this study, as well as 
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Previous studies have identified socioeconomic status and educational attainment as key risk factors 
for DKA (16). The nature of society and the cost-of care support for individuals with T1D (without 
requiring medical insurance) may substantially attenuate the impact of their impact in Finland and 
no association was observed between socioeconomic status and DKA in our cohort, after adjusting 
for alcohol use and glycaemic attainment. Some cross-sectional studies have also suggested that 
female gender is associated with an increased risk of hospitalization for DKA, despite similar overall 
indices of glucose control. By contrast, recent US data reported higher incidence of DKA 
hospitalization in males, possible as male patients with T1D present at a younger age. By 
comparison, in our prospective and retrospective cohorts we saw no association between gender 
and DKA in Finnish adults with T1D. We have previously documented higher risk-taking behaviour 
(e.g. smoking and drinking excessively) in males with T1D and a higher risk of chronic complications 
of their diabetes (6, 17).  However, after adjusting for confounding effects, gender appeared to play 
no role in incident DKA in our cohort. 
In this study, we report for the first time a strong independent association between diabetic 
nephropathy, kidney function and DKA hospitalisation. In particular, a reduced eGFR 
(<60ml/min/1.73m2) was associated with a higher risk of hospitalization for DKA. This association 
was independent of markers of glycaemic control which may also be disturbed in individuals with 
complications. It is also possible to speculate that the increasing incidence of DKA in Finnish adults 
with T1D over this time period was partly determined by the progressive decline in kidney function 
that occurred over the same time period.  It is known that the kidney plays a key role in mitigating 
the effects of hyperglycaemia and ketonaemia, such that in individuals with renal impairment 
reduced renal excretion of excess ketones and glucose alongside impaired anion exchange, may 
facilitate progression to DKA. This is a particularly important observation, as many studies of the 
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stages, and individuals with severely increased albumin excretion rates and/or reduced eGFR are 
the recruitment targets because of their high rate of renal and cardiovascular complications. It is 
now clear that this population also has an increased risk of hospitalization for DKA, making the use 
of SGLT2 inhibitors in this setting problematic. For example, there was a higher incidence of DKA 
(HR =1.6, p=0.01) in individuals with established CVD at baseline (i.e. the setting where SGLT2 
inhibition has benefits for atherothrombotic MACE in type 2 diabetes (18)). This was entirely 
explained by increased prevalence of renal impairment in this setting. 
The reason why elevated HDL cholesterol should be associated with DKA is unclear. It may be that 
HDL cholesterol is a marker of excessive alcohol intake. However, increased HDL cholesterol is also 
common in T1D, especially in women. It is thought to result from peripheral hyperinsulinemia and 
hyperadiponectinemia, leading to increased lipoprotein lipase activity which then enriches HDL with 
cholesterol following the hydrolysis of triglyceride-rich lipoproteins (19). We have previously 
described that the high HDL cholesterols subtype may be associated with an increased risk of chronic 
complications (20). It may also be that HDL cholesterol is a marker of other unmeasured risk factors 
in the diet, including ketogenic substrates (21). 
A number of previous registry publications describing prevalence and incidence of DKA have been 
based on patient self-report and short recall periods. The key strength of our study is the 
longitudinal nature of the prospective and retrospective surveys, made possible through the 
tracking of a large number of individuals with T1D using the HILMO database that captures all 
hospital admissions across Finland and records the primary diagnosis. The use of ICD-10 and ICD-9 
codes which provide for a specific code for DKA compared to ICD-8 in which DKA was included with 
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Several study limitations also need to be considered. First, the criteria to distinguish between type 
1 and type 2 diabetes used in the literature have not been validated although widely used. We used 
a cut-off of  <40 years for age at onset of diabetes in order to minimize inclusion of patients with 
type 2 diabetes, insulin therapy initiation within one year as well as a C-peptide value <0.30 nmol/l 
to ensure insulin dependence. Secondly, we only examine hospital visits (to emergency 
departments, outpatients or admission) associated with a diagnosis of DKA (or death). We do not 
include any DKA events managed out of hospital. There may be bias in which patients are sent to 
hospital and which are managed out of hospital, including disease severity, comorbidity, 
independence etc. This is conceptually similar to the endpoint of hospitalisation for heart failure 
which does not include all acute HF vents (e.g. HF treated in primary care). Nonetheless, it appears 
a valid surrogate for significant DKA events that are important to predict and prevent. Thirdly, our 
predictor studies are limited by reliance on data obtained from baseline and these factors may be 
less consistent over time, including changes in therapy, such as the initiation of CSII. Although we 
have obtained serial HbA1c data during follow-up, ongoing lipid control, alcohol use and incident 
renal impairment have not been incorporated into our analysis. Fourthly, these data are essentially 
observational, and although observational studies have a number of potential advantages, it is also 
possible that associations demonstrated in this study may be due to confounding by unmeasured 
factors or ones that are difficult to quantify. For example, DKA may be associated with a range of 
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Fiftly, we have no measures of compliance and mental health which may both influence glucose 
control and the risk for DKA (22-24). Finally, FinnDiane is an enriched cohort of adults with T1D who 
have volunteered to take part in this project. Such willing participants may have different risks to 
those in the general population, although the frequency of DKA and annualised trends were similar 
in both cohorts.  
Most DKA events are sudden, associated with a significant inter-current illness or stressor that 
liberates stress hormones including glucocorticoids, leptin, and growth hormone, which oppose the 
actions of (inadequate) insulin. Such inter-current illnesses are an unavoidable part of life. Even in 
adults with long-standing established T1D, such events can sometimes sporadically trigger DKA, 
even if there is no history of DKA events, poor glucose control, insulin pump failure or risk-taking 
behaviour. It is now clear that the potential risks for DKA never go away in T1D, even in individuals 
with no prior history of DKA. They may actually increase with time, particularly as renal function 
declines. More needs to be done to understand and mitigate these risks, and avoid these sudden 
serious events in adults with T1D who are normally well. This understanding is particularly important 
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Figure 1. The increasing frequency in incidence of hospitalization for DKA or death from DKA 
between 1996 and 2015 in adults with T1D (A) participating in the FinnDiane study (n=4758) and (B) 
in adults with T1D from the Finnish general population (n=16,219). Black circles show annualised 
rates for all DKA hospitalisations (upper line) white circles (middle line) show annualized rates for a 
DKA hospitalization that occurred in an individual who subsequently experienced no further 
admissions for DKA (i.e. one-off admissions) and triangles (lower line) shows annualised DKA 
mortality rates.  Dashed line shown mean with 95% upper and lower confidence intervals.   
Figure 2. The cumulative incidence of first hospitalization for DKA following enrolment of adults 
with T1D into the FinnDiane study, stratified according to mean and variability (coefficient of 
variation, CV) of serial HbA1c above and below the median.   
 Figure 3. The cumulative incidence of first hospitalization for DKA following enrolment of adults 
with T1D into the FinnDiane study, stratified according to diabetic nephropathy status at baseline 
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Table 1. Baseline characteristics of adults with T1D from the Finn Diane study cohort, stratified according to incident DKA during follow-up after 
enrolment. 
 No DKA events during the 
baseline visit until 2015, 
n=4,297 
At least 1 DKA event  during 
the baseline visit until 2015 
n=461 
1 DKA event  during the 
baseline visit until 2015 
n=273 
≥ 2 DKA events  during the 
baseline visit until 2015 
n=188 
Prior DKA (%) (1987-baseline) § 8.1 20.0* 19.2* 22.7* 
Insulin pump therapy (%) 4.1 8.2 * 9.0* 7.1‡ 
Sex (female %) 47.4 48.4  51.4 49.2 
Age (years) 37.9 (29.0-47.4) 38.2 (28.5-46.4) 38.7 (28.5-45.9) 36.3 (27.2-45.0) 
Age at diabetes diagnosis (years) 14.3 (9.3-23.0) 13.5 (8.9-20.9) ‡ 13.4 (9.0-20.9) 13.2 (7.8-20.8)  ‡ 
Age at diagnosis of diabetes     
           0-4 9.5 11.3 9.4 15.5 
           5-9 19.0 19.7 20.0 21.0 
           10-14 24.1 26.3 29.0 21.0 
          >=15 47.4 42.7 41.6 42.5 ‡ 
Duration of diabetes  21.4 (12.2-31.0) 23.1 (13.0-31.4) 22.9 (11.5-31.3) 22.8 (13.3-31.0) 
HbA1c (%) 8.3±1.4 9.1±1.7 * 8.9±1.6 *  9.5±1.9 * 
Intra-individual mean of HbA1c (%) 8.3 (7.6-9.1) 8.9 (8.1-9.9) * 8.8 (8.0-9.7) * 9.1 (8.4-10.3) * 
Coefficient of variability in HbA1c  0.09 (0.07-0.12)  0.11 (0.08-0.14) *  0.11 (0.08-0.14) * 0.11 (0.08-0.15) * 
Smoking history (%) || 45.8 58.8 *  61.2  * 53.2 
Alcohol consumption (yes %) 72.1 72.5 75.8 66.4 
Alcohol excess (yes %)  16.4 20.2 16.9 24.0 ‡ 
Alcohol consumption (g/week) ¶ 48 (24-90) 60 (24-120) * 48 (24-120) 72 (36-144) * 
Blue collar workers 50.0 55.1  ‡ 54.7 53.6 
     without education 16.5 21.3 21.6 18.8 
     with education 33.5 33.8 33.1 34.8 
White collar workers 24.5 21.3 21.2 23.8 
    lower 20.7 15.7 14.3 18.8 
    upper 8.3 5.6 6.9 5.0 
Other or not known 25.5 23.6 24.1 22.6 
Body Mass Index (kg/m2) 25.1±3.7 24.4±3.6 * 24.5±3.5 ‡ 24.0±3.4 * 
Waist-to-hip ratio 0.87±0.09 0.87±0.08 0.87±0.08 0.87±0.08 
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Abbreviations: DKA – diabetic ketoacidosis; ESRD – end-stage renal disease; eGFR – estimated glomerular filtration rate using CKD-EPI formula; SDR 
– severe diabetic retinopathy; hs-CRP – high sensitive CRP. *P <0.001, †P <0.01, ‡P <0.05 for comparison with no DKA; § Prior hospitalization for DKA 
as an adult (aged >18 years) and after the first two years of diabetes; || Smoking history was defined as smoking at least 1 cigarette per day for at 
least 1 year; ¶ among those who consume any alcohol; # Hypertension defined as either systolic blood pressure ≥140 mmHg or diastolic blood pressure 
≥ 90, based on the average of 2 measurements, or any use of antihypertensive medication;‡‡ Patients with ESRD excluded; # includes coronary artery 
disease and stroke  
 
Diastolic blood pressure (mmHg) 79±10 80±11 79±10 82±11 † 
Blood pressure lowering therapy (%)  42.4 52.7  * 50.2 ‡ 53.6 † 
Hypertension (%) # 56.0 62.5 † 59.6 64.1 ‡ 
Insulin dose/kg body weight (IU) 0.69±0.27 0.72±0.27 ‡ 0.70±0.28 0.75±0.27 † 
Estimated glucose disposal rate 6.3±2.5 5.6±2.4  * 5.8±2.4 † 5.3±2.3 * 
Total cholesterol (mmol/l)  4.89±0.98 5.18±1.07 * 5.15±1.10 *  5.21±1.04 *  
HDL cholesterol (mmol/l) 1.34±0.39 1.36±0.44  1.36±0.44 1.36±0.46 
Triglycerides (mmol/l) 1.02 (0.77-1.46) 1.21 (0.85-1.80) * 1.21 (0.84-1.84) * 1.25 (0.82-1.79) * 
Detectable C-peptide level (%)  21.9 18.3 22.2 13.4‡ 
Lipid lowering therapy (%) at 
baseline 
15.8 16.5 16.3 16.0 
Normoalbuminuria 61.9 48.4  * 51.2 * 45.9 * 
Microalbuminuria 12.1 12.2 11.4 13.3 
Macroalbuminuria 13.2 21.0 20.4 21.6 
Albuminuria not known 5.1 7.1 6.4 7.6 
ESRD  7.7 11.3 10.6 11.6 
eGFR (ml/min/1.73m2) ‡‡ 95 (78-110) 94 (73-112) 95 (74-112) 93 (66-112) 
eGFR< 60 ml/min/1.73m2 (%)  ‡‡ 10.8 17.9 * 18.7  18.1 † 
SDR, laser treatment (%) 33.7 43.5 * 39.5 47.2 * 
CVD (%) # 6.3 7.6 6.6 9.0 
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Table 2. Independent predictors of incident DKA in adults with T1D during the FinnDiane study 
cohort prospective follow-up period identified using Cox-regression analysis. Patients with ESRD at 
baseline were excluded for this analysis.  
 
 
 Hazard ratio 95% CI p-value 
Prior history of DKA (yes) 2.05 1.58-2.67 <0.0001 
Insulin pump therapy (yes) 2.44 1.60-3.72 <0.0001 
Smoking history (yes) 1.31 1.04-1.66 0.02 
Weekly alcohol consumption (per 10g)  1.02 1.01-1.03 0.002 
Serial HbA1c (%) 1.48 1.35-1.62 <0.0001 
HbA1c variability (per 10 percentage 
points) 
1.31 1.07-1.61 0.01 
HDL cholesterol (mmol/L) 1.82 1.36-2.45 <0.0001 
Triglycerides (mmol/L) 1.15 1.03-1.29 0.01 
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